<DOC>
	<DOCNO>NCT01044485</DOCNO>
	<brief_summary>The objective phase I/ II study therefore assess safety efficacy lapatinib combination docetaxel patient advance cancer . Only patient first line treatment metastatic disease include present study . It propose start phase I part evaluate safety lapatinib 1250 mg docetaxel 75 mg/m² without systematic support growth factor , start completion data 1000 mg lapatinib +75 mg/m² docetaxel dose level EORTC ( Bonnefoi ) study.The objective phase II part confirm safety evaluate efficacy lapatinib combination docetaxel .</brief_summary>
	<brief_title>Lapatinib Combination With Docetaxel Patients With HER-2 Positive Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>Docetaxel major drug treatment metastatic breast cancer . In HER2 negative tumor , first line treatment base docetaxel contain regimen : docetaxel alone , docetaxel + anthracycline docetaxel + capecitabine . The efficacy docetaxel combination trastuzumab demonstrate first line metastatic breast cancer overexpressing erbB2 receptor . The response rate ( RR ) time progression ( TTP ) observe even high obtain paclitaxel +trastuzumab . Docetaxel use first line metastatic setting , become first Taxane use setting.As trastuzumab may raise safety/tolerability concern , interest trastuzumab refractory patient may limit , need find new drug combine docetaxel breast cancer , address specific interaction/safety profile combination.The association lapatinib docetaxel key combination metastatic breast cancer development GSK.The conclusion phase I trial EGF 10021 trial conduct US assess combination lapatinib docetaxel show acceptable optimal tolerate regimen ( OTR ) docetaxel ( 75 mg/m² ) obtain combination lapatinib 1250 mg systematic growth factor support.Data ongoing EGF100161 phase I study evaluate OTR lapatinib + docetaxel + trastuzumab show association lapatinib 1250 mg docetaxel 75mg/m² haematological toxic recently amend evaluate lapatinib 1250 mg docetaxel 75 mg/m² systematic growth factor support.A phase I/II EORTC study evaluate docetaxel plus lapatinib neoadjuvant breast cancer patient start . The phase I part study evaluate several lapatinib docetaxel dose level conduct phase II . The phase I part enrol patient ( cohort 3 6 ) determine step-wise approach , OTR lapatinib docetaxel . Patients enter high dose level patient previous cohort complete first cycle treatment , first cycle use determine OTR . Dose modification lapatinib base observed toxicity treatment period . The OTR define dose level £ 1 6 patient experience DLT ( dose limit toxicity ) .If DLT observe first 3 patient particular dose level first cycle ( 3 week treatment period ) , recruitment start next dose levelIf 1/3 patient experience DLT particular dose level , additional 3 patient enrol dose level total 6 patient DLT occur againIf 1/6 patient experience DLT particular dose level , recruitment start next dose levelIf ³ 2/6 patient experience DLT particular dose level , dose level consider tolerableIf ³ 2/6 patient experience two distinct DLT particular dose level , additional 3 patient enrol dose level total 9 patient . If one previously describe DLT occur among new enrolled patient , dose level consider tolerableA total 12 patient treat OTR.The OTR define dose level 1 6 patient experience DLT.The DLT study define cycle 1 dose escalation step : · grade 3-4 non hematological toxicity define Common Toxicity Criteria , version 3 ( exclusion alopecia , nausea , vomit , diarrhea , infusion relate rapidly controlled appropriate measure ) · absolute neutrophil count ( ANC ) &lt; 0.5x109 /L last &gt; = 7 day· febrile neutropenia define ANC &lt; 1.0 x109 /L fever least 38.5°C· thrombocytopenia &lt; 25 , 000/µl thrombocytopenic bleed require transfusion· grade 3 high leave ventricular cardiac dysfunction ≥ 20 % decrease baseline leave ventricular ejection fraction ( LVEF ) also institution 's low limit normal ( LLN ) , confirm repeat evaluation 1 2 week follow first evaluation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Age equal 18 years· ECOG Performance Status 0 2· Patients histological cytological confirm breast cancer , HER positive ( IHC 3+ , IHC 2+ FISH/CISH + , FISH+ CISH+ ) , amenable alternative curative strategy first line metastatic setting· Patients receive hormonotherapy metastatic disease receive chemotherapy adjuvant set recurrence occur 6 month eligible· Patient must receive last injection trastuzumab within six weeks· Subjects must complete prior radiotherapy treatment least 4 week enrolment recover treatmentrelated toxicities· Subjects must tissue available prospectively determine treatment assignment compare tumor response intratumor expression level relevant biomarkers· No prior systemic investigational agent within past 30 day topical investigational drug within past 7 days· Subjects must cardiac ejection fraction within institutional range normal measure ECHO ( echocardiogram ) MUGA ( Multigated Acquisition ) scan· Subjects must adequate haematological , hepatic , renal function· Affiliation social insurance program require Subjects elevation transaminase ( ALT and/or AST ) great 2.5 time upper limit normal range ( ULN ) NOT eligible study· Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study patient recover adverse event due agent administer 4 week earlier· Patients prior treatment EGFR target therapies· All herbal ( alternative ) medicine excluded· Patients know brain metastases· History allergic reaction attribute compound similar chemical biologic composition lapatinib.· Uncontrolled intercurrent illness include , limited , ongoing active infection , peripheral neuropathy grade 2 great , psychiatric illness/social situation would limit compliance study requirements· Pregnant woman exclude study lapatinib member 4anilinoquinazoline class kinase inhibitor potential teratogenic abortifacient effects· HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction lapatinib· Patients gastro intestinal ( GI ) tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) · Current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) · Previous allergic reaction docetaxel and/or polyascorbate· Concomitant requirement medication classify CYP3A4 inducer inhibitors· Active cardiac disease , define : history uncontrolled symptomatic angina pectoris , history cardiac arrhythmia require medication , clinically significant , exception asymptomatic atrial fibrillation require anticoagulation , myocardial infarction &lt; 6 month study entry , uncontrolled symptomatic congestive heart failure , ejection fraction institutional normal limit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>HER-2 positive advance metastatic breast cancer</keyword>
	<keyword>dose escalation study</keyword>
	<keyword>lapatinib</keyword>
	<keyword>docetaxel</keyword>
</DOC>